Grifols A : Completes the sale of a 20% equity stake in SRAAS
>Grifols finally completes the Shanghai RAAS deal - The company announced the completion of the sale of a 20% stake in Shanghai RAAS to Haier Group once the deal has received all necessary regulatory approvals. The company still retains a 6.58% stake in SRAAS and a seat on their board. Grifols has received RMB12.5bn (€ 1.6bn) in cash and has entered into appropriate agreements to convert the proceeds received in local currency to euros. Grifols will use all proceeds t...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.